Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Gross Margin (2018 - 2025)

Sunshine Biopharma's Gross Margin history spans 8 years, with the latest figure at 35.31% for Q4 2025.

  • For Q4 2025, Gross Margin rose 308.0% year-over-year to 35.31%; the TTM value through Dec 2025 reached 33.76%, up 316.0%, while the annual FY2025 figure was 33.76%, 316.0% up from the prior year.
  • Gross Margin reached 35.31% in Q4 2025 per SBFM's latest filing, up from 32.64% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 64.98% in Q2 2021 to a low of 25.33% in Q2 2024.
  • Average Gross Margin over 5 years is 39.75%, with a median of 35.21% recorded in 2023.
  • Peak YoY movement for Gross Margin: crashed -3465bps in 2021, then skyrocketed 1105bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 28.0% in 2021, then skyrocketed by 35bps to 37.85% in 2022, then dropped by -12bps to 33.44% in 2023, then dropped by -4bps to 32.24% in 2024, then increased by 10bps to 35.31% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Gross Margin are 35.31% (Q4 2025), 32.64% (Q3 2025), and 36.37% (Q2 2025).